CA2609242A1 - Injectable compositions and process for preparation of such compositions - Google Patents

Abstract

Novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or .COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by intramuscular (IM) or intravenous (IV) route; process of preparing such compositions and therapeutic methods of using such compositions are provided. The analgesic and anti-inflammatory injectable compositions of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and the like, and/or chronic painful conditions, and/or a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis, and/or other associated disorders such as inflammation, fever, allergy, or the like.

Description

NOVEL INJECTABLE COMPOSITIONS AND PROCESS OF PREPARATION
THEREOF
FIELD OF THE INVENTION, The present invention relates to novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by intramuscular ;
(IM) -on:intravenous (IV) route; process of preparing such compositions and therapeutic methods of using such compositions.

The analgesic and anti-inflammatory injectable compositions of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, =l ~'1~I, ~ ,,, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and the like, and/or chronic painful conditions, and/or other associated .ll ,I1; disorders such as inflammation, fever, allergy, or the like.

BACKGROUND OF THE INVENTION
Non-steroidal anti-inflammatory drugs '(NSAIDs) and cyclooxygenase-II enzyme (COX-TP) ''inhibitors 'are' 'iri general ' higliY~",liyd'rophobic~ compounds =
and readily p'recipitate, even in''tli6 presence1 bf 'minor amounts of water. Hence it is very difficult to formulate a such compounds into injectable compositions for intramuscular or intravenous use.
NSAIDs such as nimesulide, ketorolac, diclofenac, ibuprofen and naproxen, and COX-II ' inhibitors- in''parenteral formi''capable . of instant'therapeutic action are extremely desirable: 1 In' order''tio<<prepare parenteral formulatibhs 'of 'these classes of compounds, a suita~le,'safe' and non'-toxic 'carrier/vehiclei'is requif ed in which these drugs are soluble.
Due to the physico-chemical properties of these groups of compounds, the NSAIDs or the COX-II inhibitors are poorly soluble in water hence presenting a difficulty in formulating these drugs in the parenteral fvrm. Attempts to provide NSAIDs and COX-Il inhibitory ctrugs or trieir analogs in parenteral torm using various solvents such as alcohols, dimethyl sulphoxide, propylene glycol and glycerin were found to be unsuccessful either due to problems of solubility or that when these drugs dissolve in solvents like isopropenol acid mixture, dimethyl sulphoxide and propylene glycol, the desired concentration range for the therapeutic administration of the above drugs particularly through intramuscular route does not permit the above solvent usage as they are found to be toxic. Due to such.problems, it has been extremely difficult to develop stable injectable formulation of such drugs.

Several efforts have been made in the past to inake injectable compositions comprising of NSAIDs such as nimesulide. An injectable formulation of nimesulide lias been reported in PCT Patent No. WO 95/34533 that discloses the utilization of a salt form of niniesulide with L-lysine which is in turn fiirther complexed with cyclodextrins that may be dissolved in water to give an injectable preparation. The maximum solubility achieved by this injectable co-nposition was reported to be 2.4 ing/ml, which is not sufficient for intraniuscular administration, as it would require very large volumes to administer therapeutic doses. Moreover, making a salt form of nimesulide and then combining with cyclodextrins not only makes the process cumbersome but also increases the cost of the formulations. Another reference (Daffonehio, L. et al., Inflaminatoiy Research, 45, 259-264, 1995), wherein nimesulide is dissolved in saline for intravenous adininistration for experimental studies in animals, also describes only very dilute solutions which cannot deliver therapeutic doses of nimesulide in humans.
Nimesulide is a potent non-steroidal anti-inflammatory (NSAID) drug, presently used in the treatment of painful inflammatory conditions due to rheumatoid arthritis, which also possesses antipyretic activity. Compared to other NSAIDs, nimesulide has a better therapeutic ratio, low gastrotoxicity and generally good tolerability.
Nimesulide is a strongly hydrophobic substance that is practically insoluble in water (solubility in water at room temperature being 0.01 mg/ml). Since nimesulide is insoluble in water and in a large number of non-toxic solvents specifically those which are approved for parenteral use, it becoines higllly difficult to formulate it into solutions suitable for parenteral administration via intramuscular or intravenous route. Other NSAIDs such as diclofenac, ibuprofen, indomethacin, and naproxen also offer a lot of difficulty in making them into injectable ycompositions using approved excipients and the permissible concentrations in which they are approved for parenteral use.
Parenteral compositions particularly comprising cyclooxygenase-II inhibitors sucli as rofecoxib or valdecoxib are highly unstable upon storage due to the tendency of such drugs to precipitate out, and hence it becomes difficult to obtain a homogeneous solution for parenteral administration during the shelf life of such products. It is known and well accepted that parenteral administration of drugs for the treatment of painful inflammatoiy conditions, is more effective than other routes of administration, since the drug enters the circulation directly and promptly manifests its therapeutic effect.
Seedher, Neelam et. al. (Indian Journal of Pharmaceutical Sciences, 65(1), 58-61, 2003) had described the solubility of niinesulide in various solvents and solvent-cosolvent mixtures in relation to the developinent of parenteral formulations. The said publication showed that the solubilization of nimesulide increased in semi-polar solvents such as polyethylene glycols (PEGs) and non-ionic surfactants such as Tweeng 80 and Brij x 30. However, the concetitration of PEGs used to achieve the desired solubility is too hlgh i.e. 90% which is not recommended for parenteral use specifically meant for IV
administration. US Patent Nos. 4,056,635 and 4,452,817 disclose compositions containing propofol suitable for parenteral administration to produce anesthesia in warm-blooded animals as mixtures of propofol with surfactants such as Gremophor u RH40, Cremophor EL, and Tween(I 80 in an aqueous medium that may also contain ethanol or other pharmaceutically acceptable ingredients. US Patent No.
4,794,1 17 claims a process for solubilizing indomethacin in water consisting essentially of dissolving an anti-inflammatory amount of indomethacin in a solubilizing amount of at least one polyethylene glycol having a molecular weight of 300 to 700 and dissolving the resulting solution in a solubilizing amount of an aqueous medium buffered in a pH
range of 4.5 to 8 especially intended for the external use. US Patent No.
4,798,846 discloses sterile propofol compositions containing 1% to 2% propofol alone or dissolved in oil such as arachis oil or ethyl oleate. These formulations are stabilized with surfactants. US Patent No. 5,858,999 discloses a sterile aqueous pharmaceutical composition for parenteral administration which comprises about 0.9 to about 90 mg/ml of a lazaroid or a pharmaceutically acceptable salt thereof, about 0.002 to about 2.OM
citrate, upto about 80% of a cosolvent selected from the group consisting of propylene glycol, polyethylene glycol, glycerol, ethanol, dimethylsulfoxide, dimethylacetanlide, diinethyl isosorbide, N-methyl-2-pyrrolidone and water at a pH of about 2.4 to about 3.5. These compositions use very high concentrations of cosolvents.

US Patent No. 5,688,829 assigned to the applicant of the present invention discloses a tllerapeutic injectable analgesic pharniaceutical composltion for intra-muscular administration comprising essentially nimesulide in a parenteral absorption enhancing base comprising dimethylacetamide, benzyl benzoate and etllyl oleate. The said composition uses lipophilic solvents that are oily in nature to solubilize nimesulide, which does not allow administration of the injectable via the intravenous route. Another US Patent No. 6,451,302 assigned to the same applicant describes an injectable water-miscible composition comprising nimesulide; benzyl alcohol; a substance selected fi=om the group consisting of dimethylacctainide, dimethylformamide, dimethylsulphoxide, and N-methyl pyrrolidone; and a glycol selected from the group consisting of polyethylene glycol (PEG 200 to 600), propylene glycol, hexylene glycol, butylene glycol, and polyethylene glycol 660 hydroxy stearate. The said patent necessitates the use of alkyl ainides/alkyl sulphoxides or pyrrolidones to solubilize nimesulide.

US Patent No. 6,589,973 pertains to a clear, stable novel pharmaceutical preparation of selective COX-II inhibitors in the parenteral forin for the treatment of pain and inflammatory conditions arising because of cyclooxygenase-II activity. In particular, the pharmaceutical preparation of COX-II inhibitors comprise of selective COX-lI
inhibitors such as celecoxib, rofecoxib and their analogs dissolved in a selective isosorbide type solvent. EP Patent No. 1228757 relates to stable phal-maceutical solutions suitable for parenteral administration of nimesulide consisting of 80%
glycerol forinal, 15% ethanol and 5% water and/or 75% glycerol formal, 10%
etllanol, 10% propylene glycol and 5% water. However the solvents and the concentrations in which they are used are not approved for parenteral administration. PCT
Publication No. WO 2000072884 describes a novel pharmaceutical composition of nimesulide and 2,5-di-O-methyl-1,4:3,6-dianhydro-D-glucitol with or without water, optionally containing one or more diluents which can be used for IV/IM administration or oral or topical formulations. US Publication No. 20030078266 specifically relates to a pharmaceutical composition comprising in powder forin, at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, in a therapeutically effective total amount constituting about 30% to about 90% by weight, a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and other parenterally acceptable excipient ingredients in a total amount of zero to about 10% by weight, of the composition; said composition being reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution.

The solvents used to formulate compositions intended for parenteral use should be non-toxic and should be preferably present in low concentrations. Most of the existing patent and literature references describe parenteral compositions, which comprise very high concentrations of solvents that are primarily not approved for parenteral use and also are unstable during storage.
Hence, there still exists an unmet need for developing effective non-toxic parenteral compositions comprising COX-Il inhibitors or NSAIDs in which the latter are substantially soluble, and compositions those are devoid of such aforementioned problems and which could remain stable throughout the shelf life of the product.

The inventors of the present invention have done extensive research and conducted several experiments using different non-toxic solvents and discovered that their combination in various concentrations along with suitable buffers and alkalizing agents results in a highly solubilized system suitable for parenteral administration in which the COX-II inhibitors and/or NSAIDs are soluble and which are also stable during the storage of the product thus demonstrating a significant advancement over the prior art.
SUMMARY OF THE INVENTION
It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX
inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising -a mixtui-e of glycols; optionally with other pharmaceutically acceptable excipients.

It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX
inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient; a solvent system comprising a mixture of glycols;

at least one alkalizing agent; optionally with other pliarmaceutically acceptable excipients.

It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-Il inhibitor or NSAID or COX/LOX
inhibitor, or its tautomeric forms, analogues, isoiners, polymorphs, solvates, prodrugs, or salts thereof as active ingredient; a solvent system comprising a mixture of glycols;
at least one alkalizing agent; at least one buffering agent; optionally with other pharmaceutically acceptable excipients.
It is also an objective of the present iiivention to provide novel injectable pharmaceutical compositions comprising a NSAID preferably nimesulide as active ingredient, a solvent system comprising a mixture of glycols, at least one alkalizing agent, at least one buffering agent, optionally with other pharmaceutically acceptable excipients.

It is another objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID
or COX/LOX inhibitor, or its tautomeric fonns, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more other pharmaceutically acceptable active ingredient(s).

It is another objective of the present invention to provide highly stable injectable pharmaceutical compositions suitable for intramuscular (IM) or intravenous (IV) administration.

It is yet another objective of the present invention to provide a process for the preparation of such novel injectable compositions.

It is yet another objective of the present invention to provide a process for preparation of a novel injectable pharmaceutical compositions comprising.at least one COX-II
inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forrns, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally witll other pharmaceutically acceptable excipients, which coinprises of the following steps:
i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and inixing to produce the injectable composition.

It is a still further objective of the present invention to provide a process for preparation of a novel injectable pharmaceutical coinpositions comprising at least one COX-II
inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps:
i) -adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a hoinogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by inixing, 'iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding alkalizing agent(s) to produce the injectable composition.

It is yet another objective of the present inv.ention to provide a method of using such composition which comprises administering to a patient in need thereof an effective amount of the composition.
The compositions of the present invention are particularly useful for the treatment of one or more acute painfiil conditions such as post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, or chronic painful conditions, and/or other associated disorders.

DETAILED DESCRIPTION OF THE INVENTION
The present invention describes novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient. Preferably the active ingredient is a NSAID, more preferably nimesulide. The compositions of the present invention additionally comprise a solvent system comprising a mixture of glycols, optionally with other pharmaceutically acceptable excipients.

In an embodiment, the novel injectable pharmaceutical compositions of the present invention comprise additionally at least one alkalizing agent(s) and/or at least one buffering agent(s).
In an embodiment, the novel injectable pharmaceutical composition comprises at least one COX-II inhibitor or NSAID or COX/LOX inhibitor or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts or thereof as active ingredient from about 0.1% to about 80% w/v of the composition and a solvent system comprising a mixture of glycols from about 1% to about 80% v/v of the composition;
optionally with other pharmaceutically acceptable excipients. In another embodiment, the composition of the present invention additionally comprise at least one alkalizing agent from about 0.2% to about 60% v/v of the composition and/or at least one buffering agent from about 2% to about 80% v/v of the composition.
In an embodiment, the present invention provides novel injectable pharmaceutical compositions comprising nimesulide as active ingredient, a solvent system comprising a mixture of glycols, at least one alkalizing agent, at least one buffering agent, optionally with other pharmaceutically acceptable excipients.
According to an embodiment of the present invention, the injectable compositions comprising COX-II inhibitor or NSAID or COX/LOX inhibitor can be prepared using a mixture of different non-toxic solvents in various concentrations along with suitable buffers and alkalizing agents. These compositions are clear, odorless, highly stable, non-toxic and homogeneous and are therefore suitable for parenteral administration. In an embodiment of the present invention, the injectable compositions are suitable particularly for administration by intravenous (IV) or intramuscular (IM) route.

In the present invention, the solubilization techniques used to solubilize the poorly soluble COX-II inhibitors or NSAIDs or COX/LOX inhibitor are based on cosolvation and/or pH modification techniques. Particularly, the compositions of the present invention are highly stable, preferably in the pH range of about 7.5 to 11.5, inore preferably in the pH range of about 9.0 to 11Ø

The active ingredient useful in the present invention are preferably NSAIDs selected from but not limited to a group comprising nimesulide, nabumetone, tapoxalin, diclofenac, flosulide ibuprofen, indomethacin, naproxen, and the like, their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts tliereof or COX-II
inhibitors selected from but not limited to a group comprising celecoxib, rofecoxib, valdecoxib, etoricoxib, parecoxib, itacoxib, deracoxib and the like or their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof. In an embodiment, the active ingredient of the present invention belongs to the category of COX/LOX (cyclooxygenase/lipooxygenase) inhibitor such as licofelone. In an embodiment of the preser-t invention, the active ingredient is present in the micronized form.

In an embodiment of the present invention, the novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX
inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system compi-ising a mixture of glycols; optionally with other pharinaceutically acceptable excipients, additionally comprises one or more other pharmaceutically acceptable active ingredient(s).
Other pharmaeeutically acceptable active ingredient(s) useful in the present invention is any active agent, which can be combined with a COX-II inhibitor or a NSAID or COX/LOX inhibitor, known in the art such as acetaminophen, serratiopeptidase, antibacterial agents, CNS agents, CVS agents, or the like.

In an embodiment of the present invention, the inixture of glycols used to make the solvent system is polyethylene glycol (PEG) selected from but not limited to a group comprising PEG 200, PEG 300, PEG 400, PEG 600 and PEG 700, or mixtures thereof;
and propylene glycol. In a preferred embodiment, the solvent system comprises a mixture of PEG 400 and propylene glycol.

In an embodiment of the present invention, the alkalizing agent used is an inorganic base or an organic base or a combination of both. In an embodiinent of the present invention, the alkalizing agent used is selected from but not limited to a group comprising inorganic bases such as sodium hydroxide, potassuun hydroxide, calcium hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate, magnesium oxide, and the like, or mixtures tllereof; and/or organic bases such as ineglumine, triethanolamine, diethanolamine and the like, or mixtures thereof.
In a preferred embodiment, the alkalizing agent is an inorganic base suc(1 as sodium hydroxide or potassium 1lydroxide. The alkalizing agent is preferably used as an aqueous (water) solution, prepared by dissolving the said agent in water. The quantity of the said agent and volume of water in which the agent is dissolved is used so as to obtain desired concentration of the agent.

The bufferiilg agent used in the present invention is preferably an alkaline buffering agent selected froin but not limited to a group comprising glycine buffer, lysine buffer, phosphate buffer, acetate buffer, and the like, or mixtures thereof, preferably having a pH range of about 7.2 to about 12.5. In a preferred embodiment, glycine buffer is used as the buffering agent in the-compositions of the present invention. In a still preferred embodiment, glycine buffer having pH of about 8.3 to about 11.3 is used as the buffering agent. The buffering agent is preferably used as an aqueous (water) solution, prepared by dissolving the desired compound(s) in water. The quantity of the desired compound(s) and volume of water in which the desired compound(s) is dissolved is used so as to obtain desired concentration and pH of the agent.

Pharmaceutically acceptable excipients used in the composition of the present invention are selected from but not limited to the group of excipients generally known to persons skilled in the art e.g. vehicles, bulking agents, stabilizers, preservatives, surfactants, hydrophilic polymers, solubility enhancing agents such as glycerine, various grades of polyethylene oxides, beta-cyclodextrins like sulfobutylether-beta-cyclodextrin, transcutol and glycofurol, tonicity adjusting agents, local anesthetics, pH
adjusting agents, antioxidants, osmotic agents, chelating agents, viscosifying agents, wetting agents, emulsifying agents, acids, sugar alcohol, reducing sugars, non-reducing sugars and the like, or mixtures thereof. In an embodiment, the Pharmaceutically acceptable excipient(s) is used in an amount of about 0.1% to about 70% w/v or v/v of the composition.

The vehicles suitable useful in the present invention can be selected froin but not limited to a group comprising dimethylacetamide, dimethylforniainide, dimethylsulphoxide, N-methyl pyrrolidone, benzyl benzoate, benzyl alcohol, ethyl oleate, polyoxyethylene glycolated castor oils (Cremophor EL), polyethylene glycol such as those having molecular weight of about 200 to 6000, propylene glycol, hexylene glycols, butylene glycols and glycol derivatives such as polyethylene glycol 660 hydroxy stearate (Solutrol@ HS15) and the like, or mixtures thereof.
In another embodiment of the present invention, the compositions additionally comprises an antimicrobial preservative such as benzyl alcohol preferably at a concentration of about 0.001% to about 5.0% w/w of the composition.

In yet another embodiment of the present invention, the composition additionally comprises a conventionally known antioxidant selected from but not limited to a group comprising ascorbyl palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gallate, a-tocopherol and the like, or mixtures thereof.

The compositions of the present invention are highly stable. In an embodiment, the novel compositions of the present invention may be diluted with suitable diluting fluids known to the art to prepare a solution or"dispersion or infusion before administration.
The novel compositions of the present invention are highly stable and compatible with different diluting fluids such as demineralized (DM) water, dextrose 5% w/v, sodium chloride 0.9% w/v or mixtures thereof. These fluids can be employed during the manufacture of the composition or can be used for diluting the composition before adininistration. For example, the composition is stable for 5 hrs upto 1:150 dilution and for 48 hrs up to 1:5 dilution with DM water; for 2 hrs upto 1:150 dilution and for 4 hrs upto 1:3 dilution with dextrose 5.0% solution; and for 24 hrs upto 1:150 dilution and for 48 hrs upto 1:100 dilution with 0.9% NaCI solution, particularly at room temperature.

The compositions of the present inven,Iion are preferably filled into ampoules.
Compatibility study on nimesulide injection (content of one ampoule) with different infilsion solutions were perforined to study the physical stability (during intravenous infusion) of the injection after diluting with infusion solutions. Most of the infusion solutions possess pH in acidic range (e.g. Normal saline, about 6.2; Ringer lactate solution, about 6.5 and Dextrose 5% w/v, about 5.5). Admixing with infusion solution for known injections comprising a COX-II inhibitor or NSAID or COX/LOX
inhibitor results into saturation and thus crystallization. This is not desirable for a solution if diluted as such since such solution is meant for parenteral administration.
Tllus, particularly in case of nimesulide as the active ingredient, it is requu=ed to maintain the pH of final solution at alkaline side to stabilize the nilnesulide in infusion solutloll.
Hence, compatibility studies were performed oll the Niillesulide in infilsion solutions already buffered with sodium bicarbonate to impart the alkalinity to the final solution and thus prevent recrystallization. The study showed that the illjectable composition was Iliglily stable and compatible witll different infusion solutions.

In a ful-tller embodiment, ethanol and/or dimethylacetamide (DMA) can also be added to the compositions of the present invention to furtller enhance tlle solubility of the active ingredient(s).

Stability study was conducted on the composition stated in Exalnple-I herein.
Long term (at controlled room telnpetature i.e. 25 C), intermediate (at 30 C and 70% RH), accelerated (at 40 C and 75% RH), and stress (at 60 C) stability studies were performed on the product and samples were analyzed including the controlled samples kept at freezing conditions (at 2-8 C). The product was found to be stable for lnore than six months at each of the above conditions and it did not show any stability issues relating to physical changes like particulate matter, crystallization and color change or cllemical changes such as change in potency or presence of any degl-adation product.
Furthermore, in order to assess the product stability, 'freeze-thaw cycle' study was also conducted and the product was found to be stable physically and chemically even after four freeze-thaw cycles (i.e. refrigeration of the product followed by keeping the product at 40 C and 75% RH for one day each).

In the present invention, the nimesulide injection is forlnulated preferably as an aqueous injection meant for dilution with infusion solutions particularly in case of IV
administration. Nimesulide possess pH dependent solubility i.e. nimesulide is soluble at alkaline pH and practically insoluble at acidic pH. Thus, preferably a solvent system comprising a mixture of solvents (particularly glycols) optionally along with a pH
adjusting system has been adopted to prepare a stable formulation in the present invention.

Pharmacological Study Acute toxicity study of nimesulide IV injection was carried in female Swiss mice weighing between 20-25 g (n = 6 per group). The samples used for the study were Nimesulide IV injection (Label claim: Each 3 ml contains 100 mg of nimesulide) and Placebo injection. 0.1 ml of injection equivalent to doses of 41.6, 50, 54.17, 58.3 and 83.3 mg of nimesulide per kg body weight were adininistered by IV route for 14 days.
Mice injected with 0.1 ml of injection equivalent to a dose of 50.0 mg/kg, 54.17 mg/kg, and 83.3 mg/Icg showed toxic symptoms of decreased locomotor activity, stupor, and tremors. Mice injected at dose level of 41.6 mg/kg and 5inl/kg placebo did not show any toxic symptom. The mortality rate of 16.6 %, 50 %, and 100% was observed at dose levels of 54.17 mg/kg, 58.3 mg/kg, and 83.3 mg/kg respectively. The LD50 of the nimesulide injection (IV) was found to be 57.54 mg/kg.

Acute toxicity study of nimesulide IM injection was carried out in female Swiss mice weighing between 20-25 g (n = 5 per group). The samples used for the study were Nimesulide IM injection (Label claim: Each 3 ml contains 100 mg of nimesulide) and Placebo injection. The dose given was 1.25, 2.5, 5, 6.25, and 7.5 m1/kg of Nimesulide IM injection equivalent to 41.6, 83.3, 166.67, 208.33, and 250 mg of nimesulide per 1cg body weight respectively by IM route for 14 days. No toxicity symptoms were observed at dose level of 41.6 mg/kg of nimesulide injection and with 2.5 m1/1cg placebo injection in mice. Mice injected with a dose of 83.3, 166.67, 208.33 or 250 mg/kg showed toxicity symptoms. The' mortality rates of 40%, 80%, and 100% were observed at dose level of 166.67 mg/kg, 208.33 mg/kg, and 250 mg/kg respectively. The LD50 of the nimesulide injection when administered intramuscularly was found to be 173.78 mg/kg.

A study was conducted to compare the hemolytic potential of Nimesulide IV
injection 100 mg/ml of the present invention with that of commercially available IV/IM
injections on Rat whole blood (citrated) and Rat packed red blood cells (citrated). The cominercially available IV/IM injections used for the study were Diazepam injection 5 mg/ml (CALMPOSEO), Diclofenac sodium injection 25 mg/ml (VOVERANO), Frusemide injection 10 mg/ml (LASIXO), Nimesulide injection 10% w/v (NIMOVETO), and Pentazocin lactate injection 30 mg/ml (FORTWINO). The study showed that Nimesulide IV injection of the present invention when tested (at blood to test sample ratio of 1:10) on Rat packed red blood cells (citrated) showed comparative fractions of healthy ce11s as compared to CALMPOSEO, FORTWINO, NIMOVETO
and VOVERANO. Nimesulide IV injection when tested (at blood to test sample ratio of 13:1) on Rat whole blood (citrated) showed coinparative fractions of healthy cells as compared to CALMPOSEO, FORTWINO, and LASIXO.

The perivenous tolerance following a single intravenous administration of Nimesulide IV
injection 100 mg/3 ml of the present invention against a placebo composition was studied in rabbits. The study showed that the animals injected intravenously witli Nimesulide IV
injection of the present invention or the placebo did not show any signs of local irritation at the site of injection in the right ears.

Pharmacokinetic study of Nimesulide IV injection of the present invention was carr_ied out in rabbits. Albino rabbits (1.9-2.1 kg) of either sex (n=4 rabbits) were selected for the study. Nimesulide IV injection, each 2 ml ampoule containing 75 mg nimesulide, was used. A dose of 3.75 mg/kg body weight of rabbit equivalent to human dose of 75 mg/601cg were administered by IV route, via marginal ear vein of rabbits and blood sampling was done at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hour intervals, and the plasma samples were analyzed for nimesulide by LC-MS/MS. The pharmacokinetic profile of Nimesulide injection in rabbits is presented below:
Table-1: Pharmacokinetic profile of Nimesulide injection in rabbits S. No. Time (in hours) Average Plasma concentration of Nimesulide (microgram/mi) 1 0 0.00 2 0.25 17.00 3 0.5 15.90 4 1 13.35 5 1.5 10.73 6 2 8.57 7 2.5 8.18 8 3 7.83 9 4 6.26 6 3.10 5 11 8 1.41 12 10 0.62 13 12 0.24 14 24 0.00 In a further embodiment of the present invention, a process for the preparation of such 10 novel injectable compositions is provided.

In an embodiment, the process for preparation of a novel injectable pharinaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX
inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solveilt system coinprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps:
i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.

In another embodiment, the process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor and/or NSAID
or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more biuffering agent(s) and/or alkalizing agent(s), which comprises of the following steps:
i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding alkalizing agent(s) to produce the injectable composition.

In another embodiment, the process as described herein comprises the active ingredient selected from a group comprising of at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof, optionally with one or more additional active ingredient(s) that can be combined with a COX-II inhibitor or NSAID known to art. Preferably the NSAID is nimesulide or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.

In yet another embodiment of the present invention, therapeutic methods of use of such compositions are provided. The analgesic and anti-inflammatory injectable compositions of the present invention are useful for the treatment of acute painfiil conditions like post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and the like, in mammals particularly in humans and animals, more particularly in humans.

In a further embodiment, the present invention provides a method of using the novel injectable pharmaceutical composition, which comprises administering to a patient in need thereof an effective amount of the composition.
In a further embodiment, the present invention provides a method of using the injectable pharmaceutical composition preferably for the treatment of acute and/or chronic painful conditions in mammals particularly mammals, including a variety of painful and inflammatory coilditions like postoperative pain, primary dysmenorrhea and painful osteoarthritisand/or other associated disorders such as inflammation, fever, allergy, or the like.

In a further embodiment, the present invention provides a method of using the injectable pharmaceutical composition particularly for the treatment of acute painful conditions, wllerein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis.

In a further embodiment is provided the use of the compositions of the present iiivention for the preparation of medicament for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and/or chronlc painful conditions, and/or painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis and/or other associated disorders such as inflammation, fever, allergy, or the like.
Some typical examples illustrating embodiments of the present invention are provided.
However, it should also be understood that the particular compositions, processes and methods illustrating the present invention are exemplary only and should not be regarded as limitations of the present invention.

EXAMPLES
Example-1: Nimesulide Injection (100 mg/3 ml) S. No. Ingredients Quantity/ 100 ml 1. Polyethylene glycol (PEG-400) 30.00 ml 2. Propylene Glycol 20.00 ml 3. Glycine Buffer pH 11.3 36.00 ml 4. Nimesulide 3.34 gm 5. Sodium hydroxide (NaOH) solution 4.0% w/v 11.20 ml Procedure:
i) Talce specified quantity (30-.00 m1)'of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer.
iii) Add about 30.0 ml of the Glycine Buffer pH 11.3 to the step (ii) wath continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesli to the step (iii) with continuous stirring.

v) Add specified quantity (11.20 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 ml.

viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.
Example-2: Diclofenac Injection (75 mg/3 ml) S. No. Ingredients Quantity/ 100 ml 1. Polyethylene glycol (PEG-300) 30.00 ml 2. Propylene Glycol 20.00 ml 3. Glycine Buffer pH 12.0 30.00 ml 4. Diclofenac 2.50 gm 5. Sodium hydroxide (NaOH) solution 4.0% w/v 10.00 ml Pi=ocedure:
i) Take specified quantity (30.00 ml) of PEG-300 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring.
iii) Add about 25.0 nil of the Glycine Buffer pH 12.0 to the step (ii) with continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of Diclofenac passed through #60 mesh to step (iii).
v) Add specified quantity (10.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffe-- to step (vi).
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 7.5 by adding NaOH 4.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.
Example-3: Indomethacin Injection (25 mg/3 ml) S. No. Ingredients Quantity/ 100 ml 1. Polyethylene glycol (PEG-400) 30.00 ml 2. Propylene Glycol 20.00 ml 3. Lysine Buffer pH 10 42.00 ml 4. Indomethacin 0.84 gm 5. Sodium hydroxide (NaOH) solution 4.0% w/v 11.20 ml Procedure:
i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.

ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring.
iii) Add about 36.0 ml of the Lysine Buffer to the step (ii) with continuous stirring.
iv) Add weighed amount of Indomethacin passed through #60 mesh to step (iii).
v) Add specified quantity (11.20 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Lysine Buffer to step (vi).
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 11.5 by adding NaOH 4.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.
Example-4: Rofecoxib Injection (25 mg/3 ml) S. No. Ingredients Quantity/ 100 ml l. Polyethylene glycol (PEG-400) 20.00 ml 2. Propylene Glycol 20.00 ml 3. Dimethylacetamide 10.00 ml 4: Glycine Buffer pH 11.3 36.00 ml 5. Rofecoxib 0.84 gm 6. Sodium hydroxide (NaOH) solution 4.0% w/v 12.00 nil Procedure i) Take specified quantity (20.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer. Add 10.00 ml of Dimethylacetamide and mix.
iii) Add about 30.0 ml of the Glycine Buffer pH 11.3 to step (ii).
iv) Add weighed amount of Rofecoxib passed through #60 mesh to step (iii).
v) Add specified quantity (12.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 ml.
viii) Mix the solution for about 10 minutes by continuous stii-ring.
ix) Adjust final pH to 11.0 by adding NaOH 4.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.

Example-5: Licofelone Injection (100 mg/3 ml) S. No. Ingredients Quantity/ 100 ml 1. Polyethylene glycol (PEG-400) 30.00 ml 2. Propylene Glycol 20.00 ml 3. Glycine Buffer pH 11.3 36.00 nzl 4. Licofeloile 3.34 gm 5. Sodium hydroxide (NaOH) solution 3.0% w/v 14.40 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring, iii) Add about 30.0 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of licofelone passed through #60 mesh to step (iii).
v) Add specified quantity (14.40 ml) of NaOH 3.0% solution to tlle step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity ofGlycine Buffer pH 11.3 to make up the volume to 100 ml.
viii) Mix the solution for about 10 ininutes by continuous stirring.
ix) Adjust final pH to 10.0 by adding NaOH 3.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.
Example-6: Nimesulide Injection (100 mg/3 ml) S. No. Ingredients Quantity/ 100 ml 1. Polyethylene glycol (PEG-400) , 30.00 ml 2. Propylene Glycol 20.00 ml 3. Glycine Buffer pH 11.3 36.00 ml 4. Nimesulide micronized 3.34 gm 5. Sodium hydroxide (NaOH) solution 5.0% w/v 11.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring.
iii) Add about 30.0 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a homogeneous mixture.

iv) Add weighed amount of Nimesulide micronized passed through #60 mesh to the step (iii) with continuous stirring.
v) Add specified quantity (11.00 ml) of NaOH 5.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the vohIme to 100 ml.
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 10.0 by adding NaOH 5.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.
Example-7: Nimesulide Injection (100 mg/3 ml) S. No. Ingredients Quantity/ 100 ml l. Polyethylene glycol (PEG-400) 30.00 ml 2: Propylene Glycol 20.00 ml 3. Glycine Buffer pH 11.3 36.00 ml 4. Nimesulide 3.34 gm 5. Potassium hydroxide (KOH) solution 5.6 % w/v 11.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring.
iii) Add about 30.0 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesh to the step (iii) with continuous stirring.
v) Add specified quantity (11.00 ml) of KOH 5.6% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 ml.
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 11.0 by adding KOH 5.6% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.

Example-8: Nimesulide Injection (100 mg/3 ml) S. No. Ingredients Quantity/ 100 ml 1. Polyethylene glycol (PEG-400) 30.00 ml 2. Propylene Glycol 10.00 ml 3. Glycine Buffer pH 11.3 46.00 ml 4. Nimesulide 3.34 gm 5. Potassium llydroxide (KOH) solution 4.0 % w/v 13.80 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (10.00 ml) to step (i) with continuous stirring.
iii) Add about 40.0 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesh to the step (iii) with continuous stirring.

v) Add specified quantity (13.80 ml) of KOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remauling quantity of Glycine Buffer pH 11.3 to make up the volunle to 100 ml.
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 11.0 by adding KOH 4.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.
Example-9: Nimesulide Injection (100 mg/3 ml) S. No. Ingredients Quantity/ 100 ml 1. Polyethylene glycol (PEG-600) 20.00 ml 2. Propylene Glycol 10.00 ml 3. Phosphate Buffer pH 7.2 56.00 ml 4. Nimesulide 3.34 gm 5: Potassium hydroxide (KOH) solution 5.6 % w/v 11.20 ml Procedure i) Take specified quantity (20.00 ml) of PEG-600 into a vessel.
iij Add Propylene glycol (10.00 ml) to sten (i) with continuous stirring.

iii) Add about 50.0 ml of the Phosphate Buffer pH 7.2 to the step (ii) with continuous stirring to form a homogeneous mixture.

iv) Add weighed amount of Nimesulide (3.34 gm) passed through 960 mesh to the step (iii) with continuous stirring.

v) Add specified quantity (11.20 ml) of KOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity ofPhosphate Buffer pH 7.2 to make up volume to 100 inl.
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 11.0 by adding KOH 5.6% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.
Example-10: Nimesulide Injection (100 mg/3 ml) S. No. Ingredients ' Quantity/ 100 ml 1. Polyethylene glycol (PEG-300) 30.00 ml 2. Glycine Buffer pH 11.3 56.00 ml 3. Nimesulide micronized 3.34 gm 4. Potassium hydroxide (KOH) solution 6.5 % w/v 9.50 ml Procedure i) Take specified quantity (30.00 inl) of PEG-300 into a vessel.
ii) Add about 40.0 ml of the Glycine Buffer pH 11.3 to the step (i) with continuous stirring to form a homogeneous mixture.
iii) Add weighed amount of Nimesulide micronized passed through #60 mesh to the step (ii) with continuous stirring.
iv) Add specified quantity (9.50 ml) =of KOH 6.5% solution to the step (iii) with continuous stirring to form a homogeneous solution.
v) Mix the solution for about 30 minutes by continuous stirring.
vi) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 ml.
vii) Mix the solution for about 10 minutes by continuous stirring.
viii) Adjust final pH to 9.5 by adding KOH 6.5% w/v solution.
ix) Mix the solution for about 10 minutes by continuous stirring.

Example-11: Nimesulide injection (75mg/2m1):
S. No. Ingredients Quantity/ 100 -nl 1. Nimesulide micronized 3.77 (Y-2. Polyethylene Glycol (PEG 400) 30.00 m1 3. Propylene Glycol 20.00 ml 4. Glycine Buffer pH 11.3 35.00 ml 5. NaOH solution 4.0% 13.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring.
iii) Add about 30.00 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a llomogeneous mixture.
iv) Add weighed amount of Nimesulide (3.75 g) passed through #60 mesh to the step (iii) with continuous stirring.
v) Add specified quantity (13.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 -nl.
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.
Example-12: Licofelone injection (100 mg/3 ml):
S. No. Ingredients Quantity/ 100 ml 1. Licofelone 3.34 g 2. Polyethylene Glycol (PEG-400) 30.00 ml 3. Propylene Glycol 20.00 ml 4. Glycine Buffer pH 11.3 30.00 ml 5. NaOH solution 4.0% . 15.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer.

iii) Add about 28.00 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of Licofelone (3.34 g) passed through #60 mesh to the step (iii) with continuous stirring.
v) Add specified quantity (15.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volLune to 100 ml.
viii) Mix the solution for about 10 ininutes by continuous stirring.
ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution.
x) Mix the solution for about 10 minutes by contuluous stirring.
Example-13: Parecoxib injection (50 mg/2 ml):
S. No. Ingredients Quantity/ 100 ml 1. Parecoxib 2.50 g 2. Polyethylene Glycol (PEG-400) 30.00 ml 3. Propylene Glycol 20.00 ml 4. Glycine Buffer pH 11.3 34.00 ml 5. NaOH solution 4.0% 14.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer.
iii) Add about 30.00 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of Parecoxib (2.50 g) passed through #60 mesh to the step (iii) with continuous stirring.
v) Add specified quantity (14.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 ml.
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution.

x) Mix the solution for about 10 minutes by continuous stirring.

Example-14: Diclofenac Sodium injection (75 mg/2 ml):
S. No. Ingredients Quantity/ 100 nil 1. Diclofenac Sodium 3.77 g 2. Polyethylene Glycol (PEG-400) 30.00 ml 3. Propylene Glycol 20.00 ml 4. Glycine Buffer pH 11.3 35.00 ml 5. NaOH solution 4.0% 13.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.
ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer.
iii) Add about 30:00 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of Diclofenac sodium (3.77 g) passed tllrough #60 mesh to the step (iii) with continuous stirring.
v) Add specified quantity (13.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity ofGlycine Buffer pH 11.3 to make up the volume to 100 inl.
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 10.0 by adding NaOI-i 4.0% w/v solution.
x) Mix the solution for about 10 minutes by contimious stirring.
Example-15: Ibuprofen injection (200 n1g/2 ml):
S. No. Ingredients Quantity/ 100 ml 1. Ibuprofen 10 g 2. Polyethylene Glycol (PEG-400) 30.00 ml 3. Propylene Glycol 20.00 ml 4. Glycine Buffer pH 11.3 25.00 ml 5. NaOH solution 4.0% 18.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel.

ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring.
iii) Add about 22.00 ml of the Glycine Buffer pH 11.3 to the step (ii) with continuous stirring to form a homogeneous mixture.
iv) Add weighed amount of Ibuprofen (10.00 g) passed through #60 mesh to the step (iii) with continuous stirring.
v) Add specified quantity (18.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homo=geneous solution.
vi) Mix the solution for about 30 minutes by continuous stirring.
vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 ml.
viii) Mix the solution for about 10 minutes by continuous stirring.
ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution.
x) Mix the solution for about 10 minutes by continuous stirring.

Claims (34)

1. A novel injectable pharmaceutical composition comprising at least one COX-II
inhibitor or NSAID or COX/LOX inhibitor or its tautomeric forms, or its analogues, isomers, polymorphs, solvates, prodrugs, or salts or thereof as active ingredient from 0.1% to 80% w/v and a solvent system comprising a mixture of glycols from 1% to 80% v/v; optionally with other pharmaceutically acceptable excipients.

2. A composition according to claim 1, wherein the said composition additionally comprises at least one alkalizing agent from 0.2% to 60% v/v.

3. A composition according to claim 1, wherein the said composition comprises at least one buffering agent from 2% to 80% v/v.

4. A composition according to claims 1 to 3, wherein the COX-II inhibitor is selected from a group comprising celecoxib, rofecoxib, valdecoxib, etoricoxib, parecoxib, itacoxib, deracoxib or their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof.

5. A composition according to claims 1 to 3, wherein the NSAID is selected from a group comprising nimesulide, nabuinetone, tapoxalin, diclofenac, flosulide, ibuprofen, indomethacin, naproxen or their tautomeric forms, analogues, isomers, polymorphs, solvates, pro.drugs, or salts thereof.

6. A composition according to claim 5, wherein the NSAID is nimesulide or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.

7. A composition according to claim I, wherein the COX/LOX inhibitor is licofelone.

8. A composition according to claims I to 7, wherein the active ingredient is in the micronized form.

9. A composition according to claim 1, wherein the solvent system comprises a mixture of polyethylene glycol and propylene glycol.

10. A composition according to claim 9, wherein the polyethylene glycol (PEG) is selected from a group comprising PEG 200, PEG 300, PEG 400, PEG 600 and PEG 700, or mixtures thereof.

11. A composition according to claim 10, wherein the solvent system comprises a mixture of PEG 400 and propylene glycol.

12. A composition according to claim 2, wherein the alkalizing agent is selected from a group comprising inorganic bases and/or organic bases.

13. A composition according to claim 12, wherein the inorganic base is selected from a group comprising sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate and magnesium oxide, or mixtures thereof.

14. A composition according to claim 12, wherein the organic base is selected from a group comprising meglumine, triethanolamine and diethanolamine, or mixtures thereof.

15. A composition according to claim 3, wherein the buffering agent is an alkaline buffering agent.

16. A composition according to claim 15, wherein the alkaline buffering agent is selected from a group comprising glycine buffer, lysine buffer, phosphate buffer and acetate buffer, or mixtures thereof, having a pH of about 7.2 to about 12.5.

17. A composition according to claim 16, wherein the buffering agent is glycine buffer having a pH of about 8.3 to about 11.3.

18. A composition according to claim 1, wherein the pharmaceutical excipients are selected from a group comprising vehicles, bulking agents, stabilizers, preservatives, surfactants, hydrophilic polymers, solubility enhancing agents, tonicity adjusting agents, local anesthetics, pH adjusting agents, antioxidants, osmotic agents, chelating agents, viscosifying agents, wetting agents, emulsifying agents, acids, sugar alcohol, reducing sugars and non-reducing sugars, either alone or in combination thereof, used in an amount of about 0.1%
to about 70% w/v or v/v of the composition.

19. A composition according to claim 18, wherein the solubility enhancing agent is selected from a group comprising glycerine, various grades of polyethylene oxides, beta-cyclodextrins, transcutol and glycofurol, or mixtures thereof.

20. A composition according to claim 18, wherein the vehicle is selected from a group comprising dimethylacetamide, dimethylformamide, dimethylsulphoxide, N-methyl pyrrolidone, benzyl benzoate, benzyl alcohol, ethyl oleate, polyoxyethylene glycolated castor oils, polyethylene glycol, propylene glycol, hexylene glycols, butylene glycols and glycol derivatives, or mixtures thereof.

21. A composition according to claims 1 to 20, which additionally comprises an antimicrobial preservative.

22. A composition according to claims 1 to 21, which additionally comprises an antioxidant.

23. A composition according to claim 22, wherein antioxidant is selected from a group comprising ascorbyl palmirate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gallate and .alpha.-tocopherol, or mixtures thereof.

24. A composition according to claims 1 to 23, wherein ethanol and/or dimethylacetamide is added to further enhance the solubility of the active ingredient.

25. A composition according to claims 1 to 24, wherein the injectable compositions are suitable for parenteral administration by intravenous or intramuscular route.

26. A process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-Il inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps:
i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.

27. A process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols;
optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps:
i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding alkalizing agent(s) to produce the injectable composition.

28. A process according to claims 26 or 27, wherein the active ingredient is selected from a group comprising of at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs;-or salts thereof.

29. A process according to claim 28, wherein the NSAID is nimesulide or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.

30. A method of using the injectable pharmaceutical composition according to claim 1, which comprises administering to a patient in need thereof an effective amount of the composition.

31. A method of using the injectable pharmaceutical composition according to claim 30, for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, postoperative pain, primary dysmenorrhea, painful osteoarthritis, and/or other associated disorders such as inflammation, fever, or allergy.

32. Use of a composition according to claim 1 for the preparation of a medicament for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, postoperative pain, primary dysmenorrhea, painful osteoarthritis, and/or other associated disorders such as inflammation, fever, or allergy.

33. The pharmaceutical compositions substantially as herein described and illustrated by the examples.

34. The processes for the preparation of pharmaceutical compositions substantially as herein described and illustrated by the examples.